Diabetes Research Institute
Diabetes is one of the toughest challenges of our time in terms of public health. Ospedale San Raffaele, where diabetes is one of the central themes of research and assistance, in 2007 has gradually institutionalized and consolidated its commitment through the creation of the Diabetes Research Institute (DRI).
The DRI is composed of 8 units of basic research, 5 units of clinical groups and 2 facilities. View all the research units here.
The DRI is an international center of excellence for the study, prevention and treatment of diabetes. This goal is pursued through a number of clinical programs in concert with research projects, often extended to the Institute’s internal and external collaborations, especially international.
Among the many programs that exist within the DRI, some are of particular strategic importance. Examples are: transplantation of pancreatic islets and cell therapies for the induction of immunological tolerance, prevention of type 1 diabetes, modern technologies (eg. insulin pumps and artificial pancreas), study and prevention of diabetes complications and programs of cardio-diabetes and cardio-metabolism in type 2 diabetes. The final outcome of such research is the development of clinical studies to test new hypotheses for the cure of the disease (phase 1 and 2 studies) or improve current therapies (phase 3 studies).
Head, Immune-mediated diseases Unit
Group leader, Experimental diabetes Unit
Group leader, Regulation of adaptive immunity Unit
Group leader, Cardiodiabetes and core Lab Unit
Group leader, Transplant immunology Unit
Pier Marco Piatti
Clinical group leader, Cardiometabolism and clinical trials Unit
Head, Beta cell biology Unit
Group leader, Metabolism, nutrigenomics and cell differentiation Unit
Group leader, Complication of diabetes Unit
Beta cell biology
Cardiodiabetes and core Lab
Cardiometabolism and clinical trials
Pier Marco Piatti
Complication of diabetes
Metabolism, nutrigenomics and cell differentiation
Regulation of adaptive immunity